Communiqués Eli Lilly and Company

Actions

LLY

US5324571083

Produits pharmaceutiques

Marché Fermé - Nyse Autres places de cotation 22:00:02 13/06/2025			Varia. 5j.	Varia. 1 janv.
819,36 ^USD	+0,90 %		+6,43 %	+6,13 %

15/06	Eloralintide d'Eli Lilly fait baisser le poids lors d'un essai précoce	MT
14/06	Le médicament expérimental contre l'obésité d'Eli Lilly montre une perte de poids de plus de 11 % lors des premiers essais	RE

Communiqués

Apotex Not Entitled To Damages For Delayed Generic Drug Launch	05/06	AQ
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins	03/06	AQ
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference	02/06	PR
New Eli Lilly acquisition to progress potential next-generation pain treatment	28/05	AQ
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics	27/05	PR
Lilly's Kisunla receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease	22/05	AQ
Eli Lilly and : An open letter regarding access and insurance coverage for people living with obesity	22/05	PU
Eli Lilly and Company - Zepbound showed superior weight loss over Wegovy in complete SURMOUNT-5 results published in The New England Journal of Medicine	12/05	AQ
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine	12/05	PR
Lilly announces transitions in executive leadership	08/05	PR
Lilly declares second-quarter 2025 dividend	05/05	PR
Lilly to participate in Bank of America Securities 2025 Healthcare Conference	02/05	PR
Lilly: Q1 Earnings Snapshot	01/05	AQ
Eli Lilly and : 2025 Earnings Presentation	01/05	PU
Eli Lilly and : 2025 Press Release	01/05	PU
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum	01/05	PR
Commodity Supercycle Spotlight: Power Metallic (TSXV: PNPN \| OTCQB: PNPNF) Expands High-Grade Copper-Gold Zone-More Stocks Under $2 Gaining Traction	01/05	AQ
Eli Lilly to lead oligonucleotide therapy development in new collaboration	30/04	AQ
Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds	23/04	AQ
Chugai Pharmaceutical - Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron	21/04	AQ
Eli Lilly releases topline data for new oral GLP-1	18/04	AQ
Lilly confirms date and conference call for first-quarter 2025 financial results announcement	17/04	PR
Eli Lilly and : 2025 Estimated Acquired IPR&D And Development Milestone Charges	10/04	PU
Canadian scientist wins Breakthrough Prize for discovery of hormone used in Ozempic, Mounjaro	06/04	AQ
Knownwell Connects with LillyDirect to Increase Access to Independent Comprehensive Metabolic Care Options for Patients Across the U.S.	03/04	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Eli Lilly investit 27 milliards pour de nouvelles usines malgré les menaces douanières

Le 26 février 2025 à 16:23

Le PDG d'Eli Lilly parle de la lutte contre le cancer et l'obésité et de la fixation du prix des médicaments

Le 13 janvier 2025 à 17:30